- Feb. 10, 2020
-- Growth in geriatric population, coupled with the rising incidence of chronic diseases, is resulting in an increased number of surgeries across the world. Along with advancements in healthcare technology, these have become the major growth factors for the global adhesion barrier market (https://www.psmarketresearch.com/
market). Valued at $541.3 million in 2017, the domain is expected to generate revenue of $833.1 million by 2023, progressing at a CAGR of 7.5% during forecast period.
Adhesion barrier is a physical barrier applied between the layers of tissue during surgery, so that operated-upon tissues do not overlap with other tissues and organs while healing. Once the surgical site heals, the barrier itself is dissolved and absorbed by the body. The adhesion barrier market has been segmented by product, formulation, application, and geography. Adhesion barriers are available in two product types: synthetic and natural. Of the two, synthetic adhesion barriers were preferable during the historical period 2013–2017, owing to their higher flexibility and bioabsorbility. In 2017, these made a revenue contribution of 67.2% to the market.Download sample copy of this report at: https://www.psmarketresearch.com/market-analysis/adhesion-barrier-market/report-sample
In recent years, due to the increase in health issues across the world, the number of surgeries, such as abdominal and gynecological surgeries, has risen considerably. Gel, film, and liquid-based adhesion barriers are generally used in these surgeries. With the rise in the number of surgeries performed around the world, the demand for these products has also increased, hence driving the adhesion barrier market.
Key players of the adhesion barrier market, such as Johnson & Johnson, MAST Biosurgery AG, and Anika Therapeutics Inc., have witnessed significant prosperity due to the progress in the domain in recent years. With increased revenue, they are spending more on the research and development of new products to broaden their portfolio. In a recent industry development of 2017, Actamax Surgical Materials LLC received the USFDA approval to put its sprayable and bioabsorbable Actamax adhesion barrier through clinical trials.
Thus, it is clear that the sector will continue to prosper during the forecast period owing to the rise in surgeries, increase in awareness about surgical and post-surgical risks, and advancements in the adhesion barrier technology.